Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1)

Biochemical Pharmacology

Volumn 67, Issue 8, 2004, Pages 1541-1548

  Hooijberg, Jan Hendrik ^a   Jansen, Gerrit ^a   Assaraf, Yehuda G ^b   Kathmann, Ietje ^a   Pieters, Rob ^c   Laan, Adrie C ^a   Veerman, Anjo J P ^a   Kaspers, Gertjan J L ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

ABCC1; Daunorubicin; DHFR; Dihydrofolate reductase; DNR; Folate; Folylpolyglutamyl synthetase; FPGS; HF; High folate; L leucovorin; LF; Low folate; LV; Methotrexate; MRP1; MTX; Multidrug Resistance Protein; Reduced folate carrier; RFC; Thymidylate synthase; TS

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; BENZBROMARONE; DAUNORUBICIN; FOLIC ACID; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TRANSPORT; FOLIC ACID BLOOD LEVEL; HOMEOSTASIS; HUMAN; HUMAN CELL; OVARY CARCINOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT; DAUNORUBICIN; FEMALE; FOLIC ACID; FOLIC ACID DEFICIENCY; GENE EXPRESSION; HUMANS; NUCLEOTIDES; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 1642332919     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.12.022     Document Type: Article

References (43)

1. Borst P., Elferink R.O. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 71:2002;537-592.
2. Leslie E.M., Deeley R.G., Cole S.P.C. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology. 167:2001;3-23.
3. König J., Nies A.T., Cui Y., Leier I., Keppler D. Conjugate export pumps of the multidrug resistance protein (MTP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochem. Biophys. Acta. 1461:1999;377-394.
4. Bertino J.R. Ode to methotrexate. J. Clin. Oncol. 11:1993;5-14.
5. Cronstein B.N. Methotrexate and its mechanism of action. Arthritis Rheum. 39:1996;1951-1960.
6. Hooijberg J.H., Broxterman H.J., Kool M., Assaraf Y.G., Peters G.J., Noordhuis P., Scheper R.J., Borst P., Pinedo H.M., Jansen G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 59:1999;2532-2535.
7. Kool M., Van der Linden M., De Haas M., Scheffer G.L., De Vree M.L., Smith A.J., Jansen G., Peters G.J., Ponne N., Scheper R.J., Oude Elferink R.P.V., Baas F., Borst P. MRP3, a new organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. U.S.A. 96:1999;6914-6918.
8. Zeng H., Chen Z.S., Belinsky M.G., Rea P.A., Kruh G.D. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of poly-glutamylation on MTX transport. Cancer Res. 61:2001;7225-7232.
9. Lee K., Klein-Szanto A.J., Kruh G.D. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J. Natl. Cancer Inst. 92:2000;1934-1940.
10. Chen Z.S., Lee K., Walther S., Blanchard Raftogianis R., Kuwano M., Zeng H., Kruh G.D. Analysis of methotrexate and folate transport by Multidrug Resistance Protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 62:2002;3144-3150.
11. Sirotnak F.M., Wendel H.G., Bornmann W.G.B., Tong W.P., Miller V.A., Scher H.I., Kris M.G. Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. Clin. Cancer Res. 6:2000;3705-3712.
12. Kusuhara H., Han Y.H.M., Shimoda M., Kokue E., Suzuki H., Sugiyama Y. Reduced folate derivatives are endogenous substrates for cMOAT in rats. Am. J. Physiol. 275:1998;G789-G796.
13. Stark M., Rothem L., Jansen G., Scheffer G.L., Goldman I.D., Assaraf Y.G. Antifolate resistance associated with loss of MRP1 expression and function in Chinese hamster ovary cells with markedly impaired export of folate and cholate. Mol. Pharmacol. 64:2003;220-227.
14. Hooijberg J.H., Peters G.J., Assaraf Y.G., Kathmann I., Priest D.G., Bunni M.A., Veerman A.J., Scheffer G.L., Kaspers G.J., Jansen G. The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis. Biochem. Pharmacol. 65:2003;765-771.
15. Assaraf Y.G., Rothem L., Hooijberg J.H., Stark M., Ifergan I., Kathmann I., Dijkmans B.A., Peters G.J., Jansen G. Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J. Biol. Chem. 278:2003;6680-6686.
16. Jansen G., Mauritz R., Drori S., Sprecher H., Kathmann I., Bunni M., Priest D.G., Noordhuis P., Schornagel J.H., Pinedo H.M., Peters G.J., Assaraf Y.G. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J. Biol. Chem. 273:1998;30189-30198.
17. Zhao R., Gao F., Liu L., Goldman I.D. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of the folate cofactor pools within tumor cells. Biochem. Pharmacol. 61:2001;857-865.
18. van der Wilt C.L., Backus H.H., Smid K., Comijn L., Veerman G., Wouters D., Voorn D.A., Priest D.G., Bunni M.A., Mitchell F., Jackman A.L., Jansen G., Peters G.J. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res. 61:2001;3675-3681.
19. Habeck L.L., Chay S.H., Pohland R.C., Worzalla J.F., Shih C., Mendelsohn L.G. Whole-body disposition and polyglutamate distribution of the GAR formyltransferase inhibitors LY309887 and lometrexol in mice: effect of low-folate diet. Cancer Chemother. Pharmacol. 41:1998;201-209.
20. Broxterman H.J., Kuiper C.M., Schuurhuis G.J., van der Hoeven J.J., Pinedo H.M., Lankelma J. Daunomycin accumulation in resistant tumor cells as a screening model for resistance modifying drugs: role of protein binding. Cancer Lett. 35:1987;87-95.
21. Scheffer G.L., Kool M., Heijn M., de Haas M., Pijnenborg A.C., Wijnholds J., van Helvoort A., de Jong M.C., Hooijberg J.H., Mol C.A., van der Linden M., de Vree J.M., van der Valk P., Elferink R.P., Borst P., Scheper R.J. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res. 60:2000;5269-5277.
22. Wielinga P.R., Heijn M., Westerhoff H.V., Lankelma J. A method for studying plasma membrane transport with intact cells using computerized fluorometry. Anal. Biochem. 263:1998;221-231.
23. Ruiz van Haperen V.W.T., Veerman G., Boven E., Noordhuis P., Vermorken J.B., Peters G.J. Schedule dependence of sensitivity to 2′,2- difluorocytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumor cell lines and solid tumors. Biochem. Pharmacol. 48:1994;1327-1339.
24. Bergman A.M., Ruiz van Haperen V.W.T., Veerman G., Kuiper C.M., Peters G.J. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin. Cancer Res. 2:1996;521-530.
25. Jhaveri M.S., Wagner C., Trepel J.B. Impact of extracellular folate levels on global gene expression. Mol. Pharmacol. 60:2001;1288-1295.
26. Zingg J.M., Jones P.A. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis. 18:1997;869-882.
27. Kool M., de Haas M., Scheffer G.L., Scheper R.J., van Eijk M.J., Juijn J.A., Baas F., Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57:1997;3537-3547.
28. Hollo Z., Homolya L., Hegedus T., Muller M., Szakacs G., Jakab K., Antal F., Sarkadi B. Parallel functional and immunological detection of human multidrug resistance proteins, P-glycoprotein and MRP1. Anticancer Res. 18:1998;2981-2987.
29. Evers R., de Haas M., Sparidans R., Beijnen J., Wielinga P.R., Lankelma J., Borst P. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br. J. Cancer. 83:2000;375-383.
30. Jansen G., Westerhof G.R., Jarmuszewski M.J.A., Kathmann I., Rijksen G., Schornagel J.H. Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. J. Biol. Chem. 265:1990;18272-18277.
31. Yang C.H., Sirotnak F.M., Mines L.S. Further studies on a novel class of genetic variants of the L1210 cell with increased folate analogue transport inward. Transport properties of a new variant, evidence for increased levels of a specific transport protein, and its partial characterization following affinity labeling. J. Biol. Chem. 263:1988;9703-9709.
32. Jansen G., Barr H.M., Kathmann I., Bunni M., Priest D.G., Noordhuis P., Peters G.J., Assaraf Y.G. Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration. Mol. Pharmacol. 55:1999;761-769.
33. Worm J., Kirkin A.F., Dzandzhugazyan K.N., Guldberg P. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. J. Biol. Chem. 276:2001;39990-40000.
34. McGuire J.J., Bertino J.R. Enzymatic synthesis and function of folylpolyglutamates. Mol. Cell. Biochem. 38:1981;19-48.
35. Shane B. Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism. Vitam. Horm. 45:1989;263-335.
36. Ma L., Krishnamachary N., Center M.S. Phosphorylation of the multidrug resistance associated protein gene encoded protein P190. Biochemistry. 34:1995;3338-3343.
37. Olszewski A.J., McCully K.S. Homocysteine metabolism and the oxidative modification of proteins and lipids. Free Radic. Biol. 14:1993;683-693.
38. Borst P., Evers R., Kool M., Wijnholds J. The multidrug resistance protein family. Biochem. Biophys. Acta. 1461:1999;347-357.
39. Loe DW, Deeley RG, Cole SP. Characterization of vincristine transport by the Mw 190,000 kDa multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res. 1998;5130-6.
40. Rappa G., Finch R.A., Sartorelli A.C., Lorico A. New insights into the biological and pharmacology of the multidrug resistance protein (MRP) from gene knochout models. Biochem. Pharmacol. 58:1999;557-562.
41. Priest D.G., Schmitz J.C., Bunni M.A., Stuart R.K. Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. J. Natl. Cancer Inst. 83:1991;1806-1812.
42. Peters GJ, van der Wilt CL, Groeningen CJ, Priest DG, Schmitz J, Smid K, Meijer S, Noordhuis P, Hoekman K, Pinedo HM. Effect of different leucovorin formulations on 5-fluorouracil induced thymidylate synthase inhibition in colon tumors and normal tissues from patients in relation to response to 5-fluorouracil. In: Pfleider W, Rokos H, editors. Chemistry and biology of ptteridines and folates. Berlin: Blackwell Science; 1997. p. 145-50.
43. Peters G.J., Jansen G. Folate homeostasis and antiproliferative activity of folates and antifolates. Nutrition. 17:2001;737-738.